Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis And Inactivated Polio Vaccine has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis And Inactivated Polio Vaccine studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
711866/006 (dTpa-IPV-006) III A phase III, open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ dTpa-IPV vaccine when administered as a booster vaccination to healthy children aged 6-8 years and previously vaccinated with 4 doses of DTPw and at least 3 doses of OPV/ IPV vaccines. dTpa-IPV: GSK Biologicals’ combined reduced antigen content diphtheria, tetanus, acellular pertussis and inactivated polio vaccine. DTPw: combined diphtheria, tetanus, whole cell pertussis vaccine. OPV: Oral polio vaccine, IPV: Inactivated polio vaccine.